JO
ACAD icon

John Overdeck’s Acadia Pharmaceuticals ACAD Stock Holding History

John Overdeck’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$555K – 2990
2024
Q1 		$555K Buy
+30,000
New +$743K ﹤0.01% 2286
2017
Q1 		– Sell
-42,600
Closed -$1.23M – 2835
2016
Q4 		$1.23M Buy
+42,600
New +$1.13M ﹤0.01% 1866

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

John Overdeck's ACAD Position: Q2 2026 in Review

John Overdeck increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q2 2026, buying an estimated $3.34M and bringing the position to 926,992 shares worth $23.5M. The position accounts for 0.02% of the portfolio, ranked #953.

John Overdeck first reported a position in ACAD in Q4 2016 and has held it in 25 quarters since. The position peaked at $29.9M in Q4 2025. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • John Overdeck held 926,992 shares of Acadia Pharmaceuticals worth $23.5M as of Q2 2026.
  • John Overdeck bought 151,871 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.34M.
  • Acadia Pharmaceuticals made up 0.02% of John Overdeck's portfolio in Q2 2026, its #953 holding.
  • John Overdeck first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 25 quarters since.
  • John Overdeck's Acadia Pharmaceuticals position peaked at $29.9M in Q4 2025.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.